CB 399: Hedgehog Signaling in Cancer Spring 2011

Intellectual Unit:

Hedgehog Signaling in Cancer
Course Directors: Rosalind Segal and Lee Rubin

Curriculum Fellow: Narveen Jandu, narveen_jandu@hms.harvard.edu

 The Hedgehog signaling pathway is critical for development of organisms ranging
from fruitflies to people.  This pathway is needed for the formation of diverse
organ systems, including the nervous system and the limbs.   Deregulation and
activation of this signaling pathway has been implicated in a large number of
cancers, particularly skin and brain cancers.  Mutations that activate Hedgehog
signaling have been identified in cancer predisposition syndromes and in cancer
cells.  Therefore recent efforts have been directed at developing new
antagonists that can be used to treat cancers in which the Hedgehog pathway is
activated. 

 

Schedule:

First Session: Tuesday, April 26, 2011, 1:30 - 4:30 PM
Location: TMEC Building, Rm. 109

Second Session: Friday, April 29, 2011, 1:30- 4:30 PM
Location: TMEC Building, Rm. 447

 

Assignment:

You should come prepared to address the following discussion questions:


*Registered students - please prepare a response to one of these questions and submit for credit on/before Tues May 3, 2011.

1. Describe two mechanisms by which resistance to treatment with a Smo inhibitor
might develop. 
2. The hedgehog pathway can be activated in an autocrine, paracrine or
ligand-independent fashion in cancers.  How does this change your approach to
developing treatments?
3. Describe potential combinatorial therapies that might prove to be beneficial
in various cancer.
4.  Discuss potential side effects of Hedgehog pathway antagonists that are
likely to be of concern.
5.  What are the criteria for considering the possibility that a Hedgehog
antagonist might be useful in a given type of cancer?

 

DROP DEADLINE: Tuesday, April 19, 2011

 

AUDITORS (Post-Docs, Faculty, or Staff) DO NOT NEED TO SIGN UP TO ATTEND THE 1st SESSION.  PLEASE DO NOT ENROLL.